Video blog: Test could spare some DCIS patients from radiation

Patients with heavily pretreated myeloma tended to have “really amazing results” with the CAR-T cell therapy, Carvykti.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

Even though I lost my hair from cancer treatment, I didn't let that stop me from styling my hair with attitude.

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.

Tecentriq plus Cabometyx conferred no overall survival benefit when compared with chemotherapy, a study showed.

The FDA has granted accelerated approval to Ojemda for patients 6 months and older with relapsed or refractory pediatric low-grade glioma with a BRAF fusion or rearrangement, or BRAF V600 mutation.